Illumina

The firm reported total revenues of $24.6 million, with $21.3 million in product revenue, and expects its acquisition by Illumina to be completed in Q4 2019.

The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.

The company's Q2 revenues came in above previously reported preliminary revenues of $835 million, but fell short of the analysts' estimate of $866.2 million.

The company's cofounders have developed methods for analyzing genetic material from fetal trophoblast cells isolated from the cervix.

Illumina is partnering with SV Health Investors, Sofinnova Partners, Seventure Partners, and F-Prime Capital to bring its startup incubator to Europe.

The San Diego-based firm said it expects second quarter revenues of $835 million, short of the average analyst estimate of $888 million.

As expected, the UK's Competition and Markets Authority is referring the proposed Illumina acquisition of PacBio for an in-depth Phase 2 investigation.

The suits, targeting products that include the BGISEQ-500 and MGISEQ-2000 platforms, add fuel to the ongoing patent dispute between the two firms.